The lung function profile of once-daily tiotropium and olodaterol via Respimat^® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler^® (ENERGITO^® study)

References

• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [updated February 18, 2015]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdfAccessed September 30, 2015
   Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat® plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• YohannesAMWillgossTGVestboJTiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Care201156447748721255503
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• BeehK-MWestermanJKirstenA-MThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaDiagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma – COPD Overlap Syndrome (ACOS) [updated 2014]. Available from: http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdfAccessed July 30, 2015
   Google Scholar
• RocheNPribilCVan GanseEReal-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational studyBMC Pulm Med2014145624694050
   PubMed Web of Science ®Google Scholar
• DrivenesEØstremAMelbyeHPredictors of ICS/LABA prescribing in COPD patients: a study from general practiceBMC Fam Pract2014154224597538
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• WatzHFergusonGTGrönkeLVobFAbrahamsRBuhlRInhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies [abstract]Am J Respir Crit Care Med2015191Meeting AbstractsA5784
   Google Scholar
• TriccoACStriflerLVeronikiAAComparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysisBMJ Open2015510e009183
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• LangePAumannJ-LDeromEThe 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies [abstract 4635]Eur Respir J201342suppl 57982s
   Google Scholar
• FergusonGFeldmanGHofbauerPLung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: results from two 48-week studies [abstract 187]Eur Respir J201342suppl 575s
   Google Scholar
• BeehK-MDeromEEchave-SustaetaJENERGITO: efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterolAbstract presented at: The European Respiratory Society International ConferenceSeptember 26–30, 2015Amsterdam
   Google Scholar
• QuanjerPHTammelingGJCotesJEPedersenOFPeslinRYernaultJCLung volumes and forced ventilatory flowsEur Respir J19936suppl 1654024576915
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2010 [updated 2010]. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdfAccessed August 12, 2015
   Google Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
   PubMed Web of Science ®Google Scholar
• KenwardMGRogerJHThe use of baseline covariates in crossover studiesBiostatistics201011111719915170
   PubMed Web of Science ®Google Scholar
• PisiRAielloMZaniniASmall airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2015101191119726150710
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar